Log in to your Inderes Free account to see all free content on this page.
AroCell
0.384
SEK
0 %
AROC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
0%
-5.42%
-26.86%
-4%
-12.13%
-12.73%
-52.17%
-67.93%
-83.88%
AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.
Read moreMarket cap
88.46M SEK
Turnover
64.06K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
19.2.
2025
Annual report '24
7.5.
2025
Interim report Q1'25
21.8.
2025
Interim report Q2'25
ShowingAll content types
A new study supports the use of UBC® Rapid in the follow-up of bladder cancer patients
AroCell nomination committee for the AGM 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio